Navigation Links
New test detects early-stage, asbestos-related pulmonary cancer
Date:4/4/2011

Researchers at NYU Langone Medical Center have investigated a novel protein test to detect early-stage, asbestos-related pulmonary cancer. The test can accurately identify proteins secreted from cancerous tumors caused by asbestos exposure. The study was presented at the American Association for Cancer Research 102nd Annual Meeting 2011 on April 4th.

In a blinded test performed under the sponsorship of the National Cancer Institute's Early Detection Research Network Biomarker Discovery Lab, researchers detected 15 of 19 cases of stage 1 or stage 2 malignant pleural mesothelioma. The study shows the test is approximately 80 percent sensitive in identifying disease. In addition, the specificity of the test was 100 percent with no false positives.

Malignant pleural mesothelioma is an aggressive, asbestos-related pulmonary cancer that develops in the lining of the lungs. Each year, the disease causes an estimated 15,000 to 20,000 deaths worldwide. It can be fatal within 14 months following diagnosis because of the advanced stage that it is typically found.

The goal of a new diagnostic test is to find the cancer early enough to effectively treat it, according to Harvey I. Pass, MD, director of the Division of Thoracic Surgery and Thoracic Oncology at NYU Langone Medical Center and the NYU Cancer Institute.

"The only patients that seem to benefit from therapy in mesothelioma are those that are found in stage 1, and this is only 10 to 15 percent of patients," said lead researcher Dr. Pass. "Moreover, when found early, the magnitude of the operation necessary to reduce the burden of disease may be less, making the patient better able to cope if the disease recurs and the patient needs more aggressive therapy."

The research team used the "Multiplex SOMAmer Assay" by SomaLogic, Inc. to examine 170 blood samples from 90 patients diagnosed with malignant mesothelioma and 80 participants who were previously exposed to asbestos. The technology uses SOMAmers, chemically modified single-stranded DNA molecules to bind specifically to target proteins , to identify and quantify biomarkers.

According to Dr. Pass, this test measures 19 protein biomarkers for malignant pleural mesothelioma and is able to find and quantify the small amount of proteins secreted by tumor cells. Ongoing studies are refining the test and validating the results in other patient blood samples.


'/>"/>

Contact: Lauren Woods
lauren.woods@nyumc.org
212-404-3753
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Related medicine news :

1. In Tests, Implanted Monitor Detects Atrial Fibrillation
2. Nanotech breath sensor detects diabetes and potentially serious complication
3. Molecular imaging detects recurrent prostate cancer
4. Eat safer: Novel approach detects unknown food pathogens
5. Color-changing blast badge detects exposure to explosive shock waves
6. Electronic nose detects cancer
7. MEMS thermal sensor detects pre-atherosclerotic lesions
8. Simple blood test detects early emphysema in smokers before symptoms appear
9. In pilot study, screening detects potentially serious heart conditions in healthy children
10. Vaccine for Asbestos-Related Cancer Looks Safe
11. United Therapeutics Corporation Withdraws European Marketing Authorization Application for Tyvaso for the Treatment of Pulmonary Arterial Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... ... feature 150+ Hospital and Health System Executive Speakers including: , , ... of the United States of America: George W. Bush , Boxing Legend, Successful ... Ray Leonard , JD, Chairperson, McGuireWoods LLP: Amber McGraw Walsh , ...
(Date:3/23/2017)... ... 23, 2017 , ... Sharon Kleyne, host of the nationally syndicated radio program, ... VoiceAmerica, recently talked on her program about how she is looking forward to World ... of an important distinction. World Water Day, Kleyne pointed out, is an occasion for ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... improve all aspects of people’s health and nutrition, announced its product Leyzene is ... , Natural Subsistence develops nutritional supplements that help people improve all aspects of ...
(Date:3/23/2017)... ... 23, 2017 , ... Inflow IQ & Inflownomics of Raleigh, NC introduce a ... solid foundation. As experts in dangerous situations the Inflow IQ team can help ... deliver ripe, fresh, clean & refreshing knowledge systems that enhance life. , ...
(Date:3/23/2017)... ... March 23, 2017 , ... The American Board of Quality Assurance and Utilization ... ABQAURP’s dedication to Health Care Quality and Management and Patient Safety. , It is ... the association, but also to the Health Care Quality and Patient Safety movements. Diplomates ...
Breaking Medicine News(10 mins):
(Date:3/23/2017)... March 23, 2017  The goal of the ... identify and track prescription drugs as they are distributed ... response to requirements from US FDA to better protect ... dangerous medicines. Blockchain startup Chronicled, which ... chips and blockchain technology and recently raised $6.25M, and ...
(Date:3/23/2017)... 2017 The global reprocessed ... the top five players accounting for nearly 94% ... are Stryker Sustainability Solutions, Ethicon (Johnson & Johnson), ... VANGUARD AG. Despite the high level of consolidation, ... the prevalence of fierce competition among the key ...
(Date:3/23/2017)... -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) today ... Phase 1 study of MM-310 in solid tumors. MM-310 ... taxane and targets the EphA2 receptor, a protein which ... tumor types, including prostate, ovarian, bladder, gastric, pancreatic and ... is an important step in evaluating MM-310,s safety and ...
Breaking Medicine Technology: